Post-neoadjuvant treatment of breast cancer

Achieving a pathologic complete response as a result of neoadjuvant treatment is associated with improved prognosis in breast cancer. The CREATE-X trial showed a significant survival improvement with capecitabine treatment of patients with residual invasive disease following neoadjuvant chemotherapy...

Full description

Bibliographic Details
Published in:Медицинский совет
Main Authors: V. F. Semiglazov, M. A. Dzhelialova, S. S. Yerechshenko, E. T. Munaeva, R. S. Pesotsky, A. I. Tseluyko, A. S. Emelyanov, R. V. Donskikh, P. V. Krivorotko
Format: Article
Language:Russian
Published: Remedium Group LLC 2020-07-01
Subjects:
breast cancer
post-neoadjuvant treatment
neoadjuvant systemic therapy
residual invasive tumor
potential biomarkers
Online Access:https://www.med-sovet.pro/jour/article/view/5740

Internet

https://www.med-sovet.pro/jour/article/view/5740

Similar Items